NVAX - NOVAVAX INC

10.8
0.110   1.019%

Share volume: 5,175,757
Last Updated: 03-11-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.04%

PREVIOUS CLOSE
CHG
CHG%
$10.69
0.11
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 25%
Dept financing 50%
Liquidity 45%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.37%
1 Month
28.27%
3 Months
64.38%
6 Months
35.34%
1 Year
33.33%
2 Year
113.44%
Key data
Stock price
$10.80
P/E Ratio 
2.48
DAY RANGE
$10.44 - $11.05
EPS 
$2.72
52 WEEK RANGE
$5.01 - $11.97
52 WEEK CHANGE
$32.19
MARKET CAP 
1.092 B
YIELD 
N/A
SHARES OUTSTANDING 
162.936 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
1.02
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,625,744
AVERAGE 30 VOLUME 
$5,179,719
Company detail
CEO: Stanley C. Erck
Region: US
Website: novavax.com
Employees: 1,990
IPO year: 1995
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.

Recent news